Skip to main content
Equibles
SLS logo

SLS · SELLAS Life Sciences Group, Inc. · Metrics

Track SLS — free

Use SLS with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research SLS.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$11.35 -0.79 (-6.51%) At close · Oct 22
Russell 2000 member Rebalance outlook locked
Market Cap
$2.45B
Shares
201.95M
Volume · Oct 22 6.51M Avg daily vol (3M) 6.5M

SLS metrics

65 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$11.35
Market cap
$2.45B

Price action

20 metrics
Price change (1W)
+0.1%
Price change (30D)
-5.6%
Price change (3M)
-8.0%
Price change (6M)
+144.6%
Price change (YTD)
+201.1%
Price change (1Y)
+482.1%
Trailing year
Price change (5Y)
+30.2%
52-week high
$15.46
52-week low
$1.39
Change from 52-week high
-26.6%
Change from 52-week low
+716.5%
Annualized volatility
107.6%
Annualized volatility (3M)
91.4%
Beta
2.1
RSI (14D)
47.5
Price vs SMA 50
-8.6%
Price vs SMA 200
+35.7%
Avg volume (3M)
6.50M
Relative volume
1.0
Average dollar volume
$79.52M

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
201.95M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
—
P / book
17.8
reciprocal yield 5.6%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-1.3%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-05-27

Profitability

9 metrics
Gross margin
—
Operating margin
—
Trailing 12 months
Net margin
—
Gross profit (TTM)
$0
Operating profit (TTM)
−$35.22M
Net income (TTM)
−$32.46M
Trailing 12 months
Diluted EPS (TTM)
$-0.21
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
$0.00
Gross profit per diluted share (TTM)
$0.00
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$0.46

Growth

11 metrics
Revenue growth YoY
-100.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$0
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+92.0%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-23.6%
Return on assets
-22.3%
Debt / equity
0.0
Current ratio
18.8
EBITDA (TTM)
−$5.73M
Free cash flow (TTM)
—
Quick ratio
—
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$138.34M
Latest balance sheet
Cash & equivalents
$138.34M
Total assets
$145.38M
Total debt
$0

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$28.42M
Capital expenditures (TTM)
$6,000
R&D (TTM)
$20.35M
SG&A (TTM)
$12.25M
Stock compensation (TTM)
$2.76M
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

9 metrics
13F filers
209
13F filer change QoQ
+44
Institutional ownership
51.4%
Conviction holders (share of 13F filers)
1.0%
Crowding (high-turnover and private-fund holders)
4.4%
Private-fund adviser ownership
3.7%
Active holders' share change QoQ
+57.6%
Holder tenure
9.9
Price vs estimated holder cost
+192.0%

Ownership (registered funds)

1 metrics
Index-fund ownership
16.2%

Short interest

3 metrics
Short interest
27.3%
Latest settlement · 9.5 days to cover
Days to cover
9.5d
Short-squeeze score
76 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1390478 CUSIP 81642T209 13F (30d) 33 filings 33 filers Visit website Investor relations